Founding CEO
Galapagos SpinCo
Henry Gosebruch is the Founding CEO at Galapagos SpinCo. Galapagos recently announced its intention to separate into two publicly traded companies. SpinCo will be funded with approximately EUR 2.45B in cash and focus on building a pipeline of innovative medicines with the potential to elevate standard-of-care for patients through one or more transformative transactions.
Prior to his appointment, Henry was President & CEO at Neumora Therapeutics, a biotech focused on redefining neuroscience drug development, from July 2023 until February 2025. Neumora completed its initial public offering (IPO) in September 2023. At a pre-money valuation of $2.5 billion, Neumora was one of the highest-valued recent IPOs. During his time at Neumora, the company initiated several Phase III, Phase II and Phase I clinical studies and advanced a broad pre-clinical pipeline.
Prior to his Neumora appointment, Henry was Executive Vice President and Chief Strategy Officer at AbbVie, a global biopharmaceutical company from December 2015 until February 2023. As a member of AbbVie’s Executive Leadership Team reporting to AbbVie’s CEO, he was responsible for Corporate Strategy, Competitive Strategy & Insights, Business Development & Acquisitions, Search & Evaluation, Alliance Management, R&D decision support/portfolio analytics and AbbVie Ventures. Henry and his team completed over 100 business development/M&A transactions and venture capital investments, diversifying AbbVie from its concentrated exposure to HUMIRA and building new growth businesses and pipeline opportunities. Henry and his team had a critical role in identifying and executing the acquisition of Allergan and the partnership for risankizumab (Skyrizi) that drove significant shareholder value. During his tenure, AbbVie’s market capitalization expanded from approximately $80 billion to over $275 billion.
Prior to his AbbVie appointment in 2015, Henry was Co-Head of J.P. Morgan’s North American M&A Group based in New York. He was a member of J.P. Morgan’s M&A group for more than 20 years and worked on announced M&A transactions in excess of $375 billion in total value involving companies in more than 20 countries.
Henry is a German citizen and fluent in German. He graduated magna cum laude from the Wharton School at the University of Pennsylvania in 1995 with a BSE. Henry is a member of the board of directors at Acelyrin (NASDAQ: SLRN) where he serves on the audit and transaction committees and the advisory board of the Life Sciences & Management (LSM) Program at the University of Pennsylvania. He is a licensed CPA in Illinois (inactive) and graduate of G100 Next Gen. Henry and his family live in Chicago.